Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients
2017
Abstract
Multiple sclerosis (MS) is the severe inflammatory and neurodegenerative disease of central nervous system. Unfavorable naturalcourse of MS is therapeutically changed by several effective drugs available.
These drugs are in general targeting T cell systemwhich is supposed to be critically involved in MS pathogenesis. It was surprising that very good clinical response was achieved inMS patients in large clinical trials using antiCD20 monoclonal antibody, ocrelizumab.
CD20 molecule is specifically expressed onmature B cells only. It could be delineated from these results that MS immunopathogenesis is much complex as previously thought.